The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
In a study of fifty-two patients with Graves' disease followed for 1 year after stopping antithyroid drugs, a strong relationship has been found between serum LATS-P and relapse. In those with serum LATS-P activity on stopping therapy, twenty-one (88%) out of twenty-four relapsed. In those with no LATS-P activity on stopping antithyroid drugs only eight (29%) out of twenty-eight relapsed and in five LATS-P was detectable at relapse. The overall prevalence of positive assays for LATS-P at relapse (90%) was similar to that seen in untreated Graves' disease.
D000293:Adolescent; D000328:Adult; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D008135:Long-Acting Thyroid Stimulator / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D011441:Propylthiouracil / Q000627:therapeutic use; D012008:Recurrence
D007074:Immunoglobulin G; D011441:Propylthiouracil; D002231:Carbimazole; D008135:Long-Acting Thyroid Stimulator